Floatz logo

Macitentan

Sickle Cell Disease

Boston UniversitySmall moleculePhase 2Dormant
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
65/ 100

Competitive context

135 Active assets in the Sickle Cell Disease cohort.

Asset / SponsorPhaseRating
Glutamine
Ain Shams University
Phase 4BBB
Hydroxyurea
St. Jude Children's Research Hospital
Phase 4BB
Crizanlizumab
Novartis Pharmaceuticals
Phase 4BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 4BB
MAGNESIUM METALLICUM
Medical College of Wisconsin
Phase 3BB

View all 50 →

Same molecule, other indications

Macitentan is also rated in:

idiopathic pulmonary fibrosisDormant
C
Indicative ·
36 / 100
View asset →
pulmonary hypertensionDormant
C
Indicative ·
33 / 100
View asset →
glioblastomaDormant
D
Indicative ·
25 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →